Octreotide: A 15-year update

Endocrinologist

Volumn 16, Issue 2, 2006, Pages 86-90

  Comi, Richard J ^a,b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Acromegaly; Carcinoid; Octreotide; Receptor; Somoatostatin

Indexed keywords

GROWTH HORMONE ANTIBODY; OCTREOTIDE; PEGVISOMANT; RADIOISOTOPE; SOMATOSTATIN DERIVATIVE; THYROTROPIN;

ACROMEGALY; CARCINOID; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; DRUG INDICATION; DRUG INHIBITION; ENDOCRINE DISEASE; ENDOCRINE TUMOR; GASTROINTESTINAL DISEASE; GLUCAGONOMA; HEALTH CARE MANAGEMENT; HUMAN; HYPERTHYROIDISM; HYPOKALEMIA; HYPOPHYSIS TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUSTAINED RELEASE PREPARATION; VERNER MORRISON SYNDROME; VIPOMA;

EID: 33748453056     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ten.0000203247.66715.c0     Document Type: Review

References (54)

1. Wenzel E, Comi RJ. Use of octreotide in clinical endocrinology. Endocrinologist. 1991;1:256-264.
2. Bauer W, Bauer U, Doepfner W, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 1982;31:1133-1140.
3. Freda P. Somatostatin analogues in acromegaly. J Clin Endocrinol Metab. 2002;87:3013-3018.
4. Stewart PM, Kane KF, Stewart SE, et al. Depot long acting somatostatin analog (Sandostatin LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab. 1995;80:3267-3272.
5. Kaal A, Orskov H, Nielsen S, et al. Occurrence and effects of octreotide antibodies during nasal, subcutaneous and slow release intramuscular forms. Eur J Endocrinol. 2000;143:353-361.
6. Jaquet P, Saveanu A, Gunz G, et al. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. J Clin Endocrinol Metab. 2000;85:781-792.
7. Delaunoit T, Rubin J, Necczyporenko F, et al. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors. Mayo Clin Proc. 2005;80:502-506.
8. Ballare E, Persani L, Lania AG, et al. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab. 2001;86:3809-3814.
9. Colao A, Ferone D, Marzullo P, et al. Long term effects of depot long acting somatostatin analogue octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab. 2001;86:2779-2786.
10. Socin HV, Chanson P, Delemer B, et al. The changing spectrum of TSH secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol. 2003;148:433-442.
11. Trautman AR, Creutzfeld W, Benning R, et al. Somatostatin analogue octreotide and inhibition of tumor growth in metastatic endocrine gastroenteropancreatic tumours. Gut. 1996;38:430-438.
12. Leong WL, Pasieka JL. Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature. J Surg Oncol. 2002;79:180-187.
13. Nikou GC, Toubanakis C, Nikolaou P, et al. VIPomas: an update in diagnosis and management in a series of 11 patients. Hepatogastroenterology. 2005;52:1259-1265.
14. Chastain MA. The glucagonoma syndrome: a review of its features and discussion of new perspectives. Am J Med Sci. 2001;321:306-320.
15. Gotzsche PC. Somatostatin analogues for acute bleeding oesophageal varices. Cochrane Database Syst Rev. 2002;1:CD000193.
16. Corley DA, Cello JP, Adkisson W, et al. Octreotide for acute esophageal variceal bleeding: a meta analysis. Gastroenterology. 2001;120:946-954.
17. Klingenberg RD, Homann N, Ludwig D. Type 1 intestinal lymphangiectasia treated successfully with slow release octreotide. Dig Dis Sci. 2003;48:1506-1509.
18. Shi W, Johnston CF, Buchanan KD, et al. Localization of neuroendocrine tumors with 111 In DPTA octreotide scintigraphy: a comparative study with CT and MR imaging. QJM. 1998;91:295-301.
19. Burgess JR, Greenway TM, Paraneswaran V, et al. Octreotide improved biologic, radiologic, and symptomatic indices of gastropancreatic neoplasia in patients with MEN-1 syndrome. Cancer. 1999;86:2154-2159.
20. Vezzosi D, Bennet A, Rochaix P, et al. Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with OctreoScan scintigraphy and immunostaining with antisst2A and antisst5 antibodies. Eur J Endocrinol. 2005;152:757-767.
21. Angeletti S, Corleto VD, Schillaci O, et al. Use of somatostatin analogue octreotide to localize and manage somatostatin producing tumors. Gut. 1998;42:792-794.
22. Neild PJ, Evans DF, Castillo FD, et al. Effect of octreotide on small intestinal motility in HIV infected patients with chronic refractory diarrhea. Dig Dis Sci. 2001;46:2636-2642.
23. Suc B, Msika S, Piccinini M, et al. Octreotide in the prevention of intra-abdominal complications following elective pancreatic resection: a prospective multicenter randomized controlled trial. Arch Surg. 2004;139:288-294.
24. Poon RT, Fan ST. Antisecretory agents for the prevention of post ERCP pancreatitis: rationale for use and clinical results. J Panc. 2003;4:33-40.
25. von Essen R, Ostermaier R, Grube E, et al. Effects of octreotide treatment on restenosis after coronary angioplasty: results of the VERAS study. Circulation. 1997;96:1482-1487.
26. Wemeau JL, Caron P, Beckers A, et al. Octreotide (long-acting release formulation) treatment in patients with Graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study. J Clin Endocrinol Metab. 2005;90:841-848.
27. Gehrs KM. Efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care. 2000;23:504-509.
28. Van Bergeijk JD, Wilson JH, Nielson OH, et al. Octreotide in patients with active ulcerative colitis treated with high dose corticosteroids. Eur J Gastroenterol Hepatol. 2002;14:243-248.
29. Lustig RH, Hinds PS, Ringwald-Smith K, et al. Octreotide therapy of pediatric hypothalamic obesity: a double blind, placebo controlled trial. J Clin Endocrinol Metab. 2003;88:2586-2592.
30. Gambineri A, Patton L, de Iasio R, et al. Efficacy of octreotide LAR in dieting women with abdominal obesity and polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:3854-3862.
31. Kwekkeboom DJ, Mueller Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogues. J Nucl Med. 2005;46(suppl 1):62S-66S.
32. Filosso PL, Ruffiani E, Oliaro A, et al. Large cell neuroendocrine carcinoma of the lung: a clinicopathological study of eighteen cases and the efficacy of adjuvant treatment with octreotide. J Thorac Cardiovasc Surg. 2005;129:819-824.
33. Dolan JT, Miltenburg DM, Granchi TS, et al. Treatment of metastatic breast cancer with somatostatin analogues - a meta-analysis. Ann Surg Oncol. 2001;8:227-233.
34. van der Lely AJ, Muller A, Janssen JA, et al. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J Clin Endocrinol Metab. 2001;86:478-481.
35. Bevan JS, Atkin SL, Atkinson B, et al. Primary medical therapy for acromegaly: an open prospective multicenter study of the effects of subcutaneous and intramuscular slow release octreotide on growth hormone, insulin like growth factor 1 and tumor size. J Clin Endocrinol Metab. 2002;87:4554-4563.
36. Melmed S, Sternberg R, Cook D, et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab. 2005;90:4405-4410.
37. Ben-Shlomo A, Melmed S. The role of pharmacotherapy in perioperative management of patients with acromegaly. J Clin Endocrinol Metab. 2002;88:963-968.
38. Biermasz NR, van Dulken H, Roelfsema F. Direct postoperative and followup results of transsphenoidal surgery of 19 acromegalic patients pre-treated with octreotide compared to those in untreated matched controls. J Clin Endocrinol Metab. 1999;84:3551-3555.
39. Cozzi R, Attanasio R, Montini M, et al. Four year treatment with octreotide long acting repeatable in 110 acromegalic patients: predictive value of short term results? J Clin Endocrinol Metab. 2003;88:3090-3098.
40. Losa M, Ciccarelli E, Mortini P, et al. Effects of octreotide treatment on the proliferation and apoptotic index of GH secreting pituitary adenomas. J Clin Endocrinol Metab. 2001;86:5194-5200.
41. Brucker-David, Oldfield EH, Skarulis MC, et al. Thyrotropin secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metab. 1999;84:476-486.
42. Comi RJ, Gesundheit N, Murray L, et al. Response of thyrotropin secreting pituitary adenomas to a long acting somatostatin analogue. N Engl J Med. 1987;317:12-17.
43. Beck-Peccoz P, Brucker-Davis F, Persani L, et al. Thyrotropin secreting pituitary tumors. Endocrine Rev. 1996;17:610-638.
44. Marsh HM, Martin JK, Kvols LK, et al. Carcinoid crisis during anesthesia: successful treatment with a somatostatin analogue. Anesthesiology. 1987;66:89-91.
45. Orbach-Zinger S, Lombarso P, Eidelman LA. Uneventful spinal anesthesia for a patient with carcinoid syndrome managed with long acting octreotide. Can J Anesth. 2002;49:678-681.
46. Ruszniewiski P, Durex M, Chayville JA, et al. Treatment of the carcinoid syndrome with the long acting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut. 1996;39:279-283.
47. O'Toole D, Ducreux M, Bommelaer G, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer. 2000;88:770-776.
48. Maton PN, D'Orisio TM, Howe BA, et al. Effect of a long acting somatostatin analogue (SMA 201-995) in a patient with pancreatic cholera. N Engl J Med. 1985;312:17-21.
49. Nguyen HN, Backes B, Lammert F, et al. Long term survival after diagnosis of hepatic VIPoma. Dig Dis Sci. 1999;44:1148-1155.
50. Granberg D, Sundin A, Janson ET, et al. OctreoScan in patients with bronchial carcinoids. Clin Endocrinol. 2003;59:793-799.
51. Van der Harst E, De Herder WW, Bruining HA, et al. 123 metaiodobenzylguanidine and 111 In octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab. 2001;86:685-693.
52. Mundschenk J, Unger N, Schulz S, et al. Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintography. J Clin Endocrinol Metab. 2003;88:5150-5157.
53. Tabarin A, Valli N, Chanson P, et al. Usefulness of somatostatin receptor scintigraphy in patients with occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab. 1999;84:1193-1202.
54. Kahaly GJ. Imaging in thyroid associated orbitopathy. Eur J Endocrinol. 2001;145:107-118.